ENUM Low Float DD pack:
ENUM is developing two antagonist PD-1 antibodies, such as ENUM 388D4 (more can be read on ENUM 388D4 here)and ENUM 244C8 for use in treating cancer.
The company is also developing antibody drug candidates for various immunomodulatory protein targets, including TIM-3, CD39, and TIGIT. Enumeral Biomedical Holdings, Inc. has collaboration agreements with Merck Sharp & Dohme Corp.; and The University of Texas MD Anderson Cancer Center, as well as a research contract with the National Cancer Institute. Other drug listings here.
The number of new cases of cancer (cancer incidence) is 454.8 per 100,000 men and women per year (based on 2008-2012 cases). The number of cancer deaths (cancer mortality) is 171.2 per 100,000 men and women per year (based on 2008-2012 deaths). Which can be read here.
Enumeral is in the process of developing novel antibody immunothrapies that help the imune system attack diseased cells.
Enumeral’s exquisite platform allows them to identify and characterize promising new drug relvant to cancer, infectious and inflammatory diseases, Giving them the potential to positively affect millions of patients whom are underserved by the current therapeutic alternatives.
The core technology behind their platform was developed and licensed from MIT, Harvard, and Whitehead institute for Biomedical research and Massachusetts General Hospital. Enumeral’s platform allows them to interrogate the human microevironment to identify and validate potential drug candidates.
The platform enables Enumeral to study rare immune cells from human patients at high resolution and measure drug effects. The platform provides a basis for developing best in class product candidates from a fundamental understanding of how immunotherapies work in each patient.
Enumeral is building a pipeline of immunomodulators that target checkpoint proteins, which the body use to prevent runaway immune responses that can prove debilitating or even deadly. The short term goal includes pre-clinical testing for their internal pipeline programs in their human-driven platform.
Currently Enumeral is engaged in multiple proof of concept collaborations with several leading pharmaceutical companies. Which has helped their technology become validated for commercial setting.
Kevin sarney’s linkdin
Interim Chief Executive Officer and President
Vice President of Finance and Chief Accounting Officer
Kevin has been Vice President of Finance and Chief Accounting Officer since 2014. Previously, he was Vice President, Finance and Administration for Avaxia Biologics, a clinical-stage biopharmaceutical company developing gut-targeted therapeutics. Prior to joining Avaxia, he served from 2009 to 2013 at various biotechnology and medical device companies in interim Vice President of Finance and Controller roles. From 2005 to 2009, Kevin was the Corporate Controller and Principal Accounting Officer of NitroMed, a publicly traded cardiovascular-focused pharmaceutical company. Kevin earned a B.S. in business management from the University of Hartford, an M.B.A. from Boston University and an M.A. in accounting from Suffolk University. He is a certified public accountant in the Commonwealth of Massachusetts.
Outstanding Shares 128,409,788 a/o Mar 24, 2017
Float 124,833,084 a/o Jun 30, 2017
ENUM 15 day Chart
1 year chart
There’s a lot of potential for ENUM to move up in our opinion. It’s near the 52 week low, and with the developing cancer drugs in their bullpen this could be a diamond in the rough. According to MorningStar the stock is undervalued.
DISCLAIMER: We do not accept any responsibility for the accuracy of the information and you make your own investment decisions! The information provided is done by our fellow associates and we do not take responsibility or reliability for its accuracy. Please do your own research before entering into a highly volatile company, you could lose the entire sum of you investment. We accept no liability for your investments.
ENUM Low Float DD pack.